{"schema_version":"secwatch.filing_event.v1","accession":"0001730430-26-000017","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.822278+00:00","generated_at":"2026-05-15T02:56:36.037557+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Kiniksa Reports Q1 2026 ARCALYST Revenue of $214.3M, Raises 2026 Guidance to $930-$945M","bullets":["ARCALYST Q1 2026 net product revenue $214.3 million, representing 56% year-over-year growth.","2026 ARCALYST net product revenue guidance raised to $930-$945 million from prior $900-$920 million.","Cash and short-term investments $468.1 million, no debt; net income $22.6 million in Q1 2026.","KPL-387 Phase 2 data in recurrent pericarditis expected in 2H 2026; Phase 3 trial by year-end.","Over 4,550 prescribers for ARCALYST in recurrent pericarditis; average therapy duration approaching 3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001730430-26-000017","json":"https://secwatch.observer/filing/0001730430-26-000017.json","markdown":"https://secwatch.observer/filing/0001730430-26-000017.md","text":"https://secwatch.observer/filing/0001730430-26-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000173043026000017/0001730430-26-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000173043026000017/knsa-20260428x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T02:56:36.037557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44d548428b2b1e57bf1cb7c3deea90329d5383c3","claim":"Kiniksa Pharmaceuticals International, plc reported the quarter ended March 31, 2026 results: revenue $214.3 million, net income $22.6 million. Guidance raised.","evidence_excerpt":"--- ​ ​ ​ ​ Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730430/000173043026000017/0001730430-26-000017-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$214.3 million"},{"label":"Net income","value":"$22.6 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}